Katherine C Saunders
Overview
Explore the profile of Katherine C Saunders including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saunders K, Shakeri A, Chu C, Drucker A, Tadrous M
Clin Rheumatol
. 2024 Aug;
43(10):3083-3088.
PMID: 39198358
Janus Kinase (JAK) inhibitors have emerged as a novel category of medications to treat a variety of immune-mediated conditions. However, limited insight exists regarding the impact of safety concerns on...
2.
Goyal S, Saunders K, Moore C, Fillo K, Ko J, Manning S, et al.
MMWR Morb Mortal Wkly Rep
. 2020 Jul;
69(29):951-955.
PMID: 32701936
Opioid use disorder and neonatal abstinence syndrome (NAS) increased in Massachusetts from 1999 to 2013 (1,2). In response, in 2016, the state passed a law requiring birth hospitals to report...
3.
Farutin V, Prodhomme T, McConnell K, Washburn N, Halvey P, Etzel C, et al.
Arthritis Res Ther
. 2019 Oct;
21(1):216.
PMID: 31647025
Background: The goal of this study is to use comprehensive molecular profiling to characterize clinical response to anti-TNF therapy in a real-world setting and identify reproducible markers differentiating good responders...
4.
Harrold L, Litman H, Saunders K, Dandreo K, Gershenson B, Greenberg J, et al.
Arthritis Res Ther
. 2018 Jan;
20(1):2.
PMID: 29329557
Background: Registry studies provide a valuable source of comparative safety data for tumor necrosis factor inhibitors (TNFi) used in rheumatoid arthritis (RA), but they are subject to channeling bias. Comparing...
5.
Harrold L, Reed G, John A, Barr C, Soe K, Magner R, et al.
Arthritis Care Res (Hoboken)
. 2017 May;
70(3):379-387.
PMID: 28544704
Objective: To assess the feasibility and efficacy of implementing a treat-to-target approach versus usual care in a US-based cohort of rheumatoid arthritis patients. Methods: In this behavioral intervention trial, rheumatology...
6.
Reed G, Collier D, Koenig A, Saunders K, Pappas D, Litman H, et al.
Arthritis Res Ther
. 2017 Apr;
19(1):81.
PMID: 28449692
Background: We examined models to predict disease activity transitions from moderate to low or severe and associated factors in patients with rheumatoid arthritis (RA). Methods: Data from RA patients enrolled...
7.
Kavanaugh A, Keystone E, Greenberg J, Reed G, Griffith J, Friedman A, et al.
Rheumatology (Oxford)
. 2017 Mar;
56(7):1095-1101.
PMID: 28340006
Objectives: To compare clinical outcomes and treatment patterns among patients with moderate vs severe RA following biologic DMARD initiation. Methods: Biologics-naive patients with moderate to severe RA [Clinical Disease Activity...
8.
Harrold L, Reed G, Kremer J, Curtis J, Solomon D, Hochberg M, et al.
Arthritis Res Ther
. 2016 Apr;
18:94.
PMID: 27118040
Background: Factors associated with care concordant with the American College of Rheumatology (ACR) recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) are unknown. Methods: We...
9.
Mease P, Collier D, Saunders K, Li G, Kremer J, Greenberg J
RMD Open
. 2016 Jan;
1(1):e000181.
PMID: 26819748
Objectives: To characterise the comparative effectiveness of combination therapy (a tumour necrosis factor inhibitor (TNFi) and a conventional synthetic disease-modifying antirheumatic drug (csDMARD) such as methotrexate) and monotherapy (TNFi only)...
10.
Strand V, Greenberg J, Griffith J, Bao Y, Saunders K, Garg V, et al.
Arthritis Care Res (Hoboken)
. 2015 Nov;
68(7):914-21.
PMID: 26555655
Objective: To assess trends and predictors of mechanical devices/aids use by rheumatoid arthritis (RA) patients since the introduction of biologic disease-modifying antirheumatic drugs (DMARDs). Methods: Sociodemographic characteristics, disease characteristics, and...